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Two Krebs cycle genes, fumarate hydratase (FH) and succinate dehydrogenase (SDH), are mutated in a subset
of human cancers, leading to accumulation of their substrates, fumarate and succinate, respectively. Here we
demonstrate that fumarate and succinate are competitive inhibitors of multiple a-ketoglutarate (a-KG)-
dependent dioxygenases, including histone demethylases, prolyl hydroxylases, collagen prolyl-4-hydroxylases,
and the TET (ten-eleven translocation) family of 5-methlycytosine (5mC) hydroxylases. Knockdown of FH and
SDH results in elevated intracellular levels of fumarate and succinate, respectively, which act as competitors
of a-KG to broadly inhibit the activity of a-KG-dependent dioxygenases. In addition, ectopic expression of
tumor-derived FH and SDH mutants inhibits histone demethylation and hydroxylation of 5mC. Our study
suggests that tumor-derived FH and SDH mutations accumulate fumarate and succinate, leading to enzymatic
inhibition of multiple a-KG-dependent dioxygenases and consequent alterations of genome-wide histone and
DNA methylation. These epigenetic alterations associated with mutations of FH and SDH likely contribute
to tumorigenesis.
[Keywords: FH; SDH; metabolites; a-KG-dependent dioxygenases; DNA methylation; histone methylation]
Supplemental material is available for this article.
Received March 7, 2012; revised version accepted May 9, 2012.
Several lines of evidence, including the recent iden-
tification of mutations affecting isocitrate dehydroge-
nase (IDH), fumarate hydratase (FH), and succinate
dehydrogenase (SDH), have demonstrated that muta-
tions in certain metabolic enzymes may play a causal
role in tumorigenesis. The NADP+-dependent IDH genes
IDH1 and IDH2 are frequently mutated in >75% of
glioma (Parsons et al. 2008), ;20% of acute myeloid
leukaemia (AML) (Mardis et al. 2009), and several
additional tumors at different frequencies (Hemerly
et al. 2010; Murugan et al. 2010; Amary et al. 2011;
Damato et al. 2012; Oermann et al. 2012). These
mutations in IDH1/2 result in simultaneous loss and
gain of activities in the production of a-ketoglutarate
(a-KG) and 2-hydroxyglutarate (2-HG), respectively
(Dang et al. 2009; Yan et al. 2009; Zhao et al. 2009).
a-KG plays critical roles in four different metabolic and
cellular pathways: as an intermediate in the Krebs cycle
for energy metabolism, as a precursor of glutamine
formation for the amino acid synthesis, as a nitrogen
transporter for the urea cycle and ammonia detoxifica-
tion, and as a cosubstrate for Fe(II)/a-KG-dependent
dioxygenases. Accumulating genetic and biochemical
evidence supports the notion that the alterations of Fe (II)/
a-KG-dependent dioxygenases contribute to tumori-
genesis (Oermann et al. 2012).
Fe(II)/a-KG-dependent dioxygenases are present in all
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on a diverse set of substrates, including proteins, alkyl-
ated DNA/RNA, lipids, antibiotics, and, most recently,
5-methylcytosine (5mC) of genomic DNA (Hausinger
2004; Loenarz and Schofield 2008; Tahiliani et al. 2009).
These enzymes require Fe(II) as a cofactor metal and
a-KG as a cosubstrate to catalyze the reactions in which
one oxygen atom from molecular oxygen (O2) is attached
to a hydroxyl group in the substrate (hydroxylation)
while the other is taken up by a-KG, leading to the
decarboxylation of a-KG and subsequent release of carbon
dioxide (CO2) and succinate. Of the >60 estimated a-KG-
dependent dioxygenases in mammalian cells (Rose et al.
2011), the JmjC domain-containing histone demethylases
(KDMs) and the TET (ten-eleven translocation) family of
DNA hydroxylases play central roles in epigenetic
control of genomic information. While the KDMs
catalyze the typical hydroxylation on the methyl group
on the lysine residue (Tsukada et al. 2006), the recently
discovered TET family of DNA hydroxylases catalyzes
a three-step iterative oxidation reaction: converting 5mC
to 5-hydroxymethylcytosine (5hmC), then converting
5hmC to 5-formylcytosine (5fC), and finally converting
5fC to 5-carboxylcytosine (5caC) (Tahiliani et al. 2009;
Ito et al. 2010, 2011; He et al. 2011). A subsequent
decarboxylation of 5caC by either a thymine–DNA
glycosylase or other DNA repair enzymes could then lead
to DNA demethylation. We and others recently demon-
strated that ectopic expression of tumor-derived mutated
IDH1 and IDH2 inhibits the activity of a-KG-dependent
dioxygenases and, more importantly, produces 2-HG,
which acts as an antagonist of a-KG to competitively
inhibit the activity of a-KG-dependent dioxygenases,
including both KDMs and TETs (Chowdhury et al. 2011;
Xu et al. 2011). These findings provide a biochemical
basis for the hypermethylation observed in human glioma
with IDH1 mutation (Noushmehr et al. 2010) and the
mutually exclusive manner of IDH1/2 and TET2 gene
mutations in AML (Lorsbach et al. 2003; Figueroa et al.
2010).
Besides IDH1 and IDH2, six genes (FH, SDHA, SDHB,
SDHC, SDHD, and SDHAF2), encoding for the subunits
of two different Krebs cycle enzymes (FH and SDH), are
mutated both germinally and somatically in a num-
ber of human cancers (Baysal et al. 2000; Astuti et al.
2001; Hao et al. 2009; Kaelin 2009; Bayley et al. 2010;
Oermann et al. 2012). Thus far, all functionally char-
acterized FH or SDH mutations result in either a com-
plete loss or reduction of enzymatic activity (Tomlinson
et al. 2002; Pollard et al. 2005), indicating that both FH
and SDH function as tumor suppressors. The tumor
suppressor roles of FH and SDH mutations have been
proposed to (1) abrogate the mitochondrial function to
trigger apoptosis (Scatena et al. 2007), (2) generate
harmful reactive oxygen species (ROS) that induce
DNA damage and genomic instability (Kaelin 2009),
and (3) provoke accumulation of HIF1a, a transcription
factor whose stabilization and elevation could promote
cell metabolism and angiogenesis (Ivan et al. 2001;
Jaakola et al. 2001; Ling et al. 2005; Selak et al. 2005).
Studies into the mechanism behind how mutations in
FH and SDH trigger elevated levels of HIF1a provided
evidence that fumarate and succinate accumulated in
cells with mutations in either FH or SDH inhibit prolyl
hydroxylases (PHDs), which hydroxylates and pro-
motes the degradation of HIF1a (Epstein et al. 2001;
Yu et al. 2001; Isaacs et al. 2005; Selak et al. 2005).
Structurally, both fumarate and succinate are similar to
a-KG and 2-HG. They have the same acetate end and
include two oxygen atoms linked to C-5 that are used by
a-KG and 2-HG to interact with conserved residues in the
dioxygenases, supporting the notion that fumarate and
succinate may function as competitive inhibitors of
a-KG-dependent dioxygenases in addition to PHDs. This
study is directed toward understanding how fumarate and
succinate alter epigenetic modifications and explores
the underlying mechanisms of FH and SDH mutations
in tumorigenesis.
Results
Both fumarate and succinate inhibit the activity
of a-KG-dependent KDMs in vitro
We showed previously that 2-HG inhibits a-KG-dependent
dioxygenases by acting as a competitive inhibitor of a-KG
(Xu et al. 2011). Likewise, fumarate and succinate also
share structural similarity with a-KG, except that
C2 with its linked oxygen atom (i.e., the ketone group)
in a-KG is absent in fumarate and succinate. In addi-
tion, fumarate and succinate differ by only one ethyl-
enic linkage (Fig. 1A). Such structural similarities make
fumarate and succinate potential antagonists of a-KG.
To test this hypothesis, we first examined the effect of
fumarate and succinate on CeKDM7A, a Caenorhabditis
elegans dual-specificity KDM that recognizes methyl-
ated H3K9, using a synthetic monomethylated H3K9
(H3K9me1) peptide as a substrate. Mass spectrometric
analysis demonstrated that a near-physiological a-KG
concentration of 15 mM could support substrate demeth-
ylation (from H3K9me1 to H3K9me0) by CeKDM7A
(Fig. 1B). The physiological concentrations of fumarate
and succinate are ;100 mM and 0.5–1 mM, respectively
(Bennett et al. 2009), and can be accumulated to high
millimolars in tumor samples with mutation of FH or
SDH (Pollard et al. 2005). Addition of 1 mM, 3 mM,
and 10 mM fumarate resulted in >80% inhibition of
CeKDM7A (Fig. 1B). Similar results were obtained using
succinate (Fig. 1B). In addition, inhibition of CeKDM7A by
fumarate or succinate became less effective, along with
increased concentrations of a-KG (Supplemental Fig. S1A).
We next examined the effect of fumarate and succi-
nate on HsKDM4A, a human histone H3K36 demeth-
ylase KDM4A/JHDM2A, using synthetic trimethylated
H3K36 (H3K36me3) as a substrate. Addition of 1 mM,
3 mM, and 10 mM fumarate led to 22%, 41%, and 73%
inhibition of HsKDM4A, respectively (Fig. 1B). Addition
of the same concentrations of succinate resulted in
43%, 68%, and 85% inhibition of HsKDM4A, respec-
tively (Fig. 1B). These results show that fumarate and
succinate can directly inhibit KDM activity. To compare
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the potency of fumarate and succinate in KDM inhibi-
tion, we determined their half maximal inhibitory con-
centration (IC50) on HsKDM4A (Fig. 1C; Supplemental
Fig. S1B). Our results demonstrated that succinate (IC50 =
0.8 mM) is more potent than fumarate (IC50 = 1.5 mM) in
inhibiting HsKDM4A (Fig. 1D).
Together, these results suggest that both fumarate and
succinate act as antagonists of a-KG to inhibit a-KG-
Figure 1. Fumarate and succinate inhibit the activity of a-KG-dependent KDMs in vitro. (A) Structural comparison among fumarate,
succinate, a-KG, and 2-HG. (B) Fumarate and succinate inhibit the demethylase activity of C. elegans KDM7A (CeKDM7A). CeKDM7A
activity toward monmethylated H3K9 was assayed in the presence or absence of 15 mM a-KG with increasing concentrations of either
fumarate or succinate as indicated. The demethylated products were analyzed by mass spectrometry (MS), and mean activity values of
duplicated assays, represented by percentage of remaining methylated peptides, are shown. (C) Fumarate and succinate inhibit the
demethylase activity of human KDM4A (HsKDM4A) toward trimethylated H3K36, determined by mass spectrometry (MS) assay as in B.
Error bars represent standard deviation (SD) for triplicate experiments. (D) Succinate is more potent to inhibit HsKDM4A than fumarate. The
half maximal inhibitory concentration (IC50) of fumarate and succinate on HsKDM4A was determined by MS assay as in C. Error bars
represent standard deviation (SD) for triplicate experiments. Additional MS results are shown in Supplemental Figure S1.
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dependent KDMs, with succinate being more potent than
fumarate.
Both fumarate and succinate increase genome-wide
histone methylations, accumulate HIF1a, and reduce
endostatin in cultured cells
Inhibition of a-KG-dependent KDMs by fumarate and
succinate in vitro led us to determine the effect of both
metabolites on genome-wide histone methylations. To
this end, we synthesized cell-permeable methyl-fumarate
and methyl-succinate, which can rapidly enter cells and
be hydrolyzed by endogenous esterases (MacKenzie et al.
2007). As expected, addition of 2.5 mM methyl-fumarate
and 5 mM methyl-succinate to the cultured HeLa cells
resulted in a significant increase of intracellular fumarate
and succinate, respectively, as determined by gas chro-
matography–mass spectrometry (GC-MS) (Supplemental
Fig. S2A). A similar increase of fumurate and succinate
was observed in HEK293T cells treated with cell-perme-
able fumarate and succinate, respectively. The fumarate/
a-KG and succinate/a-KG ratios were elevated in these
cells (Supplemental Fig. S2B). Cell-permeable fumarate
and succinate increased H3K4 monomethylation (by
fourfold), H3K27 and H3K79 dimethylation (by fourfold
and threefold, respectively), and H3K4 trimethylation (by
twofold) (Fig. 2A). Similar results were obtained in the
cultured HeLa cells after treatment with the same con-
centrations of cell-permeable fumarate and succinate
analogs (Fig. 2A).
In addition, the effect of fumarate and succinate on the
activity of two additional a-KG-dependent dioxygenases,
PHDs and collagen prolyl-4-hydroxylase (C-P4H) (Mussini
et al. 1967), was also indirectly determined by detecting
their corresponding substrate/product, HIF1a and endo-
statin. We found that cell-permeable fumarate and succi-
nate increased HIF1a and decreased endostatin in both
cell types (Fig. 2A), indicating that fumarate and succi-
nate can impair the hydroxylation of prolyl residues in
Figure 2. Fumarate and succinate increase
genome-wide histone methylations, accu-
mulate HIF1a, and reduce endostatin in
cultured cells. (A) Cell-permeable fumarate
(2.5 mM) or succinate (5 mM) increases
histone methylation and HIF1a and reduces
endostatin in HEK293T cells (left) and HeLa
cells (right), as determined by Western-blot.
(B) Cell-permeable octyl-a-KG (5mM) di-
minishes the effect of FH or SDH suppres-
sion on increasing histone methylations,
accumulating HIF1a, and decreasing endo-
statin in HEK293T cells with knockdown of
FH (left panel), SDHA (middle panel), and
SDHB (right panel), as determined by West-
ern blot. See also Supplemental Figure S3.
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HIF1a and collagen via inhibiting the enzymatic activ-
ity of PHD2 and C-P4H, respectively. The effect on
endostatin was particularly dramatic, suggesting that
C-P4H is rather sensitive to inhibition by fumarate and
succinate.
We next determined how endogenous FH and SDH
activity would affect the level of fumarate and succinate
and the activities of a-KG-dependent dioxygenases. We
found that depletion of FH and SDHA/B by siRNA re-
sulted in elevated levels of fumarate and succinate in
HeLa cells, as determined by GC-MS assay (Supplemental
Fig. S3A). Knocking down FH and SDHA/B resulted in
a significant increase of histone methylations on H3K4,
H3K9, and H3K79 (by threefold to fivefold); accumulation
of HIF1a (by fivefold); and a decrease of endostatin
(by sevenfold) (Fig. 2B). To further test the antagonistic
relationship between a-KG and fumarate or succinate,
cells with FH or SDHA/B knockdown were incubated
with cell-permeable a-KG. Addition of 5 mM octyl-a-KG
diminished the effect of FH or SDHA/B suppression on
increasing histone methylations, accumulating HIF1a,
and decreasing endostatin (Fig. 2B), and these effects of
octyl-a-KG were in a dose-dependent manner (Supple-
mental Fig. S3B).
Together, our results demonstrate that fumarate and
succinate act as competitors of a-KG to broadly inhibit
the activity of a-KG-dependent dioxygenases, including
KDMs, PHDs and C-P4Hs.
Suppression of FH or SDH expression reduces
TET-catalyzed 5hmC production in cultured cells
In addition to KDMs, PHDs and C-P4Hs, another class
of Fe(II)- and a-KG-dependent dioxygenases is the TET
family of DNA hydroxylases. Given the dependence of
TETcatalytic activity on a-KG and its inhibition by 2-HG
(Xu et al. 2011), we sought to determine whether fuma-
rate and succinate could affect TET activity and DNA
cytosine hydroxymethylation.
The 5hmC level in most cultured cells is undetectable,
but is substantially increased in cells transiently express-
ing the wild-type catalytic domain of TET1 and TET2
proteins (TET1-CD and TET2-CD) and can be easily de-
tected by immunofluorescence using an antibody specif-
ically recognizing 5hmC (Fig. 3A; Tahiliani et al. 2009;
Ito et al. 2010, 2011; He et al. 2011). HEK293T cells
with stable knockdown of FH or SDHA/B were generated
by retrovirus infection, and the knockdown efficiency
was confirmed by Western blot (Supplemental Fig. S4A).
Notably, overexpression of TET1-CD or TET2-CD was
ineffective to increase 5hmC in HEK293 cells with stable
knockdown of FH or SDHA/B, as determined by immu-
nofluorescence staining with the 5hmC-specific antibody
(Fig. 3A; Supplemental Fig. S4B,C).
To confirm the immunofluorescence data, we deter-
mined the 5hmC levels by dot blot analysis that allows
for more quantitative measurement of 5hmC (Fig. 3B–D).
Consistent with immunofluorescence results, ectopic
expression of the wild-type TET (TET1-CD and TET2-
CD), but not the catalytic mutant TET (TET1-CM and
TET2-CM), dramatically increased 5hmC levels. In cells
with stable knockdown of FH, SDHA, or SDHB, however,
overexpression of TET1-CD or TET2-CD showed signifi-
cantly less 5hmC as compared with control cells with
normal FH or SDH expression (Fig. 3B–D). Knockdown of
FH, SDHA, and SDHB reduced TET1-induced 5hmC
levels by 71%, 73%, and 82%, respectively, as compared
with control cells coinfected with retrovirus containing
the control shRNA vector pMKO. A virtually identical
result was obtained for TET2-catalyzed 5hmC produc-
tion, which was also decreased by 80%, 83% and 69% in
cells with stable knockdown of FH, SDHA, and SDHB,
respectively. The DNA amount used for dot blot analysis
was determined by methylene blue staining (Supplemen-
tal Fig. S8A).
Taken together, these data indicate that knockdown of
FH and SDHA/B leads to elevated levels of intracellular
fumarate and succinate, respectively, which act as com-
petitors of a-KG to inhibit TET-catalyzed hydroxylation
of 5mC.
Knocking down Fh or Sdha inhibits multiple
a-KG-dependent dioxygenases and regulates target
gene expression in vivo
Given our findings that knockdown of FH or SDH gene
expression broadly inhibits a-KG-dependent dioxyge-
nases in cultured cells, we sought to investigate whether
reduced expression of Fh and Sdh could affect a-KG-
dependent dioxygenases in vivo. To this end, the RNAi
approach was used to transiently knock down Fh and
Sdha in mouse livers. The siRNAs directed against Fh
and Sdha and the corresponding nontargeting scramble
siRNAs were delivered via the hydrodynamic tail vein
injection procedure to mice. At 12-h after siRNA in-
jection, we were able to achieve 62% and 78% reduction
of Fh and Sdha mRNA expression, respectively, in mouse
livers (Supplemental Fig. S7A). As a result, hepatic ex-
pression of Fh and Sdha proteins was decreased by three-
fold and twofold, respectively (Fig. 4A).
Transient knockdown of Fh or Sdha in mouse livers led
to accumulation of intracellular fumarate or succinate,
respectively, as determined by GC-MS (Supplemental
Fig. S5A,B). Notably, the succinate/a-KG ratio was also
elevated in Fh knockdown liver cells, although less
dramatically than Sdha knockdown. In contrast, the
fumarate/a-KG ratio was increased only in Fh knock-
down, but not in Sdha knockdown, liver cells (Fig. 4B).
We next determined how the accumulation of fuma-
rate and succinate would affect the activities of a-KG-
dependent dioxygenases. Transient knockdown of Fh in
mouse livers significantly increased monomethylation
on H3K4 (by 2.5-fold); dimethylation on H3K9 (by 4.2-
fold), H3K27 (by 4.3-fold), and H3K79 (by 5.2-fold); and
trimethylation on H3K4 (by 2.8-fold). Likewise, knock-
down of Sdha showed significant increases of mono-
methylation on H3K4 (by 1.9-fold); dimethylation on
H3K9 (by fourfold), H3K27 (by 3.8-fold), and H3K79 (by
4.8-fold); and trimethylation on H3K4 (by 4.3-fold) (Fig. 4A;
Supplemental Fig. S6A).
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To further substantiate the above results, we determined
mRNA expression of Hoxa genes whose up-regulation is
associated with increased H3K79 dimethylation in MLL
rearranged mouse leukemia and human AML patients
(Krivtsov et al. 2008). In line with the observed increase
of H3K79 dimethylation, mRNA expression of several
Hoxa genes (e.g., Hoxa10, Hoxa11, and Hoxa13) was up-
regulated by >10-fold in mouse livers after suppression
Figure 3. Knocking down FH or SDH reduces the TET-catalyzed 5hmC production in cultured cells. (A) HEK293T cells with stable
knockdown of FH or SDHA/B were transiently transfected with plasmids expressing the indicated proteins. Thirty-six hours to 40 h
after the transfection, cells were fixed and stained with antibodies specific to Flag to determine the expression of TET protein, with
antibodies specific to 5hmC to determine the levels of 5hmC, and with antibodies specific to DAPI to view the cell nuclei. Bars, 251
mm. See also Supplemental Figure S4. (B–D) HEK293T cells were transiently transfected as described in A. Genomic DNAs were
isolated from cells and immunoblotted with an antibody specific to 5hmC. Quantification of 5hmC was calculated from three
independent assays. The expression of individual proteins was determined by immunoblotting as shown at the right. One
representative quantification of the 5hmC level determined from the assays using 100 ng of genomic DNA is included. Error bars
represent standard deviation (SD) for triplicate experiments.
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of the Fh or Sdha gene (Fig. 4C,D). These data suggest that
accumulation of fumarate and succinate can inhibit
KDMs in mouse liver cells in vivo.
Immunohistochemical staining showed that 5hmC
was readily detectable in mouse livers (Fig. 4E). Transient
knockdown of Fh or Sdha by siRNA significantly de-
creased 5hmC in liver cells, especially near hepatic portal
veins (Fig. 4E; Supplemental Fig. S6B). In agreement, a dot
blot assay demonstrated that 5hmC production was de-
creased by 72% and 63% in the livers of Fh and Sdha
Figure 4. Knocking down Fh or Sdha inhibits multiple a-KG-dependent dioxygenases and regulates gene expression in vivo. (A) Mice
with transient knockdown of Fh or Sdha in the liver were generated by using the hydrodynamic tail vein-based delivery technique (n =
3 per group). The Fh or Sdha knockdown efficiency and levels of histone methylation, HIF1a, and endostatin were determined by
Western blot. (B) The ratios of succinate/a-KG and fumarate/a-KG in mouse livers after suppression of Fh or Sdha were determined by
GC-MS. Error bars represent standard deviation (SD) for triplicate experiments. (**) P < 0.01 versus Scramble; (n.s.) not significant. See
also Supplemental Figure S5. (C,D) The mRNA expression of Hoxa genes in mouse livers after suppression of Fh or Sdha was
determined by quantitative RT–PCR. Error bars represent standard deviation (SD) for triplicate experiments. (E,F) The 5hmC levels in
mouse livers after suppression of Fh or Sdha were determined by immunohistochemistry (E) and dot blot assay (F). Bars, 334 mm. Error
bars represent standard deviation (SD) for triplicate experiments. See also Supplemental Figure S6.
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siRNA knockdown mice, respectively (Fig. 4F; Supple-
mental Fig. S6C). Suppression of Fh or Sdha did not
significantly affect the hepatic mRNA levels of Tet
genes (Supplement Fig. S7B), indicating that transient
knockdown of Fh or Sdha would inhibit the activity of
TETs by not down-regulating the transcription of TET
genes.
Taken together, the above findings provide in vivo
evidence supporting the notion that decreased activity
of FH and SDHA leads to accumulation of fumarate and
succinate, which inhibit a-KG-dependent dioxygenases
and regulate target gene expression.
Tumor-derived FH and SDH mutants inhibit
a-KG-dependent dioxygenases
Most tumor-derived mutations targeting FH or SDH
genes cause obvious loss of function such as truncation
or frameshift (Alam et al. 2005; Bayley et al. 2008;
Bardella et al. 2011), which would eliminate the activity
of FH or SDH enzymes. There are also many missense
mutations whose exact functional consequences have not
been characterized. We next determined whether ectopic
expression of tumor-derived FH or SDH mutants would
affect the activity of endogenous a-KG-dependent dioxy-
genases. To avoid the potential effect from endogenous
proteins, cells with stable depletion of endogenous FH or
SDHA/B were generated. Then, ectopic expression of
wild-type and tumor-associated mutants were introduced
by retroviral vectors. Some of the tumor-derived FH or
SDHA/B mutants displayed a dramatic decrease of en-
zyme activity. For instance, the activity of FHR190H (the
most frequent mutation in hereditary leiomyomatosis
and renal cell cancer [HLRCC] patients) and FHH137R is
only 17% and 10%, respectively, of wild-type FH (Fig. 5A).
The activity of tumor-derived mutants SDHAG555E and
SDHAR554W is 51% and 46%, respectively, of wild-type
SDHA, and the activity of SDHBR46Q (the most frequent
SDHB mutation in paraganglioma) and SDHBA43P mu-
tants is 48% and 61%, respectively, of wild-type SDHB.
Next, we set forth to determine whether the activities
of a-KG-dependent dioxygenases would be affected in
cells expressing tumor-derived FH or SDH mutants. We
found that ectopic expression of wild-type FH or SDHA/B
resulted in decreases of dimethylation on H3K9 (by 1.5-
fold) as well as monomethylation and trimethylation on
H3K4 (by 2.5-fold and twofold, respectively), consistent
with increased KDM activity (Fig. 5B). However, these
changes in genome-wide histone methylations were not
observed in cells re-expressing tumor-derived FH or
SDHA/B mutants (Fig. 5B). Since alterations of histone
methylation will likely have a broad impact on gene
expression, we determined mRNA expression of HOXA
genes in these cells and found that knockdown of FH or
SDHA/B resulted in up-regulation of several HOXA
genes (e.g., HOXA2, HOXA4, and HOXA5). Re-expres-
sion of wild-type FH or SDH reduced HOXA gene
expression to the control levels. In contrast, re-expression
of mutant FH or SDH had no effect or even increased
HOXA gene expression (Fig. 6A).
In addition, ectopic expression of wild-type FH or
SDHA/B decreased HIF1a and increased endostatin in
cells with depletion of endogenous FH or SDHA/B as
compared with cells expressing empty pMKO vector.
These changes in HIF1a and endostatin were, again, not
found in cells re-expressing tumor-derived FH or SDHA/B
mutants (Fig. 5B). Furthermore, we investigated the
impact of tumor-derived FH and SDH mutations on
TET-catalyzed 5mC oxidation. Stable cells with deple-
tion of endogenous FH, SDHA, and SDHB displayed
much weaker 5hmC signal (29%, 27%, and 18%, re-
spectively) as compared with control pMKO cells after
transfection with TET1-CD or TET2-CD. Cotransfection
with wild-type FH, SDHA, or SDHB, but not their
mutants (i.e., FHR190H, SDHAG555E, or SDHBR46Q), could
rescue the reduction of 5hmC levels in FH or SDH stable
knockdown cells (Fig. 5C; Supplemental Fig. S8B). These
findings are consistent with the notion that accumula-
tion of fumarate or succinate in the FH or SDH knock-
down cells inhibits TET activity, thereby lowering 5hmC
levels. Re-expression of wild-type FH and SDH dramati-
cally reduced fumarate and succinate, respectively, in
the FH or SDH knockdown cells and thus increased
5hmC by relieving inhibition on TETs. In contrast, re-
expression of the tumor-derived mutants had no effect or
even increased fumarate and/or succinate levels (Fig. 6B;
Supplemental Fig. S9A–C). Together, these results in-
dicate that the tumor-derived FH and SDH mutants are
not functional in fumarate or succinate metabolism.
Accumulation of fumarate or succinate in cancer cells
containing FH or SDH mutations may contribute to
alterations of epigenetic DNA modification via inhibit-
ing TETs.
Discussion
Succinate and fumarate serve important physiological
functions in cell metabolism and could become onco-
genic when their concentrations accumulate to abnor-
mally high levels. It has been proposed that FH or SDH
mutations lead to accumulation of their substrates, fu-
marate and succinate, which bind directly to and inhibit
the activity of PHDs, leading to increased stability and
elevated levels of HIF proteins (King et al. 2006). We show
here that fumarate and succinate can also function as
a-KG antagonists to broadly inhibit a-KG-dependent
dioxygenases besides PHDs, including the JMJD family
KDMs and the TET family of 5mC hydroxylases (Fig. 7).
These observations suggest that tumor cells containing
FH or SDH mutations accumulate fumarate and succi-
nate, which then inhibit histone and DNA demethyla-
tions. Given the well-characterized tumor suppressor
function of TET, we propose that inhibition of the TET
family enzymes may contribute to tumorigenesis of FH or
SDH mutant cancer. Moreover, alterations of histone
methylation will likely have a broad impact on gene ex-
pression, which may also contribute to the tumor sup-
pressor functions of FH and SDH.
In this study, we show that the succinate/a-KG ratio is
elevated in cells expressing several tumor-derived SDH
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mutants (e.g., SDHAR554W or SDHBA43P). Considering suc-
cinate is a product of a-KG-dependent dioxygenase re-
actions, an alternative model would be that the high
levels of succinate accumulated in FH or SDH mutated
cells may inhibit the activity of a-KG-dependent dioxyge-
nases through product inhibition. However, the succinate/
a-KG ratio is not changed in cells expressing tumor-
derived FH mutants, suggesting that the product inhi-
bition mechanism may not explain the impairment of
a-KG-dependent dioxygenases in FH mutated cells. It is
also possible that the loss of function of FH or SDH in
tumorigenesis involves other mechanisms independent
Figure 5. Ectopic expression of tumor-derived FH or SDH mutants inhibits a-KG-dependent dioxygenases in cultured cells. (A)
HEK293T cells with stable FH or SDHA/B knockdown were transiently transfected with plasmids expressing the indicated proteins,
and the enzyme activity of wild-type and mutant FH or SDH was measured as described in the Material and Methods. Error bars
represent standard deviation (SD) for triplicate experiments. (**) P < 0.01 versus wild type; (##) P < 0.01 versus vector. (B) Overexpression
of tumor-derived FH or SDHA/B mutants inhibits histone demethylation and hydroxylation of prolyl residues. Levels of histone
methylation, HIF1a, and endostatin were determined by Western blot. (C) Overexpression of tumor-derived FH or SDHA/B mutants
inhibits the TET-catalyzed 5mC oxidation. 5hmC levels were determined by dot blot. Error bars represent standard deviation (SD) for
triplicate experiments.
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of the regulation of a-KG-dependent dioxygenases. Re-
cently, a new function of fumarate—covalently attaching
to cysteine residues—was reported. Fumarate can di-
rectly cause aberrant succination of many proteins, in-
cluding KEAP1 (Kelch-like ECH-associated protein 1;
an electrophile-sensitive component of an E3 ubiquitin
ligase) (Adam et al. 2011). KEAP1 is the principal regu-
lator of the nuclear factor (erythroid-derived 2)-like 2
(NRF2) via controlling its ubiquitylation and degradation,
thereby activating the antioxidant pathway (Adam et al.
2011; Ooi et al. 2011). Moreover, KEAP1 and NRF2 have
been implicated in tumor development (Taguchi et al.
2011), although their contributions to oncogenesis in FH
mutant cancer still require further exploration.
One cannot help but notice the common mechanisms
shared by mutations in the three metabolic tumor sup-
pressor genes IDH, FH, and SDH. Mutation in IDH results
in accumulation of the oncometabolite D-2-HG together
with reduction of a-KG. A common paradigm emerges
that alteration of metabolic intermediates caused by
mutations in metabolic tumor suppressors is responsible
for the tumor suppression effect of metabolic enzyme
mutations. For the group of IDH, FH, and SDH, the
common targets are the a-KG-dependent dioxygenases,
including both KDMs and DNA demethylases. These
observations suggest a possibility of manipulating me-
tabolites and/or that metabolic enzymes may provide
a potential therapeutic approach for cancer treatment. It
is well established that metabolism can be regulated by
transcription, which controls the levels of metabolic
enzyme expression. However, our study also suggests a
reciprocal mechanism: regulation of transcription by
metabolism via the changing levels of metabolic inter-
mediates—such as fumarate and succinate—that influ-
ence gene expression by epigenetic modifications.
Materials and methods
Please refer to the Supplemental Material for more detailed in-
formation about antibodies; plasmids, cell culture, and transient
transfection; GC-MS analysis; retroviral infection and genera-
tion of stable cell lines; animals; immunoprecipitation and
Western blot; quantitative real-time PCR; immunohistochemi-
cal analysis; immunofluorescence assay; and dot blot assay.
Preparation of siRNAs and siRNA treatment
For cell transfection, siRNAs targeting human FH (Gene ID:
2271), SDHA (Gene ID: 6389), and SDHB (Gene ID: 6390) were
purchased commercially (Invitrogen). siRNAs were received
as desalted, deprotected oligonucleotides. Cultured cells were
Figure 6. Tumor-derived FH or SDH mu-
tants are not functional in fumarate or
succinate metabolism. (A) HEK293T cells
with stable FH or SDHA/B knockdown
were transfected with the indicated plas-
mids. Quantitative RT–PCR was performed
to determine mRNA expression of HOXA
genes in these cells. Error bars represent
standard deviation (SD) for triplicate exper-
iments. (B) The ratios of succinate/a-KG
and fumarate/a-KG were determined by
GC-MS. Error bars represent standard de-
viation (SD) for triplicate experiments. (*)
P < 0.05 versus Scramble;; (**) P < 0.01
versus Scramble; (n.s.) not significant. See
also Supplemental Figure S9.
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transfected with siRNAs using Lipofectamin 2000 (Invitrogen).
At 4–6 h post-transfection, the culture medium was changed,
and the cells were harvested at 24–36 h after transfection.
For mouse injection, siRNAs targeting mouse Fh and Sdha
were chemically synthesized using 29Ome modification (Gene-
pharma), and their sequences are listed in Supplemental Table 1.
Synthetic siRNAs were delivered using a modified ‘‘hydrody-
namic transfection method,’’ by which 1 OD of siRNA oligo
dissolved in 1 mL of Ringer’s solution (0.9% NaCl, 0.03% KCl,
0.016% CaCl2) was rapidly injected into the tail vein. An equal
volume of normal saline was used as control. At 12 h after siRNA
injection, mouse livers were dissected, stored in 4% formalin
(Shenggong) or frozen in liquid nitrogen, and stored at 80°C
for further analysis.
Enzyme activity assay
To measure CeKDM7A demethylase activity toward dimethyl-
ated H3K9, synthetic monomethylated peptide corresponding to
monomethylated H3K9 (ARTKQTARK (me1)STGGKA) was
used as substrate. Demethylase assays were carried out in the
presence of 10 mg of enzyme, 1 mg of peptide in 20 mL of buffer (20
mM Tris-HCl at pH 7.5, 150 mM NaCl, 50 mM (NH4)2Fe(SO4)2,
100 mM a-KG, 2 mM Vc, 10 mM PMSF] for 3 h. The demethy-
lation reaction mixture was desalted by passing through a C18
ZipTip (Millipore). To examine the inhibitory effect of fumarate
or succinate on the reaction, various concentrations of fumua-
rate or succinate were incubated with KDM7A briefly before
adding other reaction mixtures. The samples were analyzed by
a MALDI-TOF/TOF mass spectrometer.
To measure HsKDM4A demethylase activity toward tri-
methylated H3K36, synthetic trimethylated peptide correspond-
ing to trimethylated H3K36 (RKSAPATGGVK(me3)KPHRY) was
used as substrate. A construct encoding HsKDM4A residues
1–357 was amplified by PCR and cloned into pET28a-His. After
purification, the activity of the enzyme (10 mg each tube) was
measured as described above.
For the FH enzyme activity assay, cells were collected at 36 h
after transient transfection with wild-type or mutant FH plas-
mids. After immunoprecipitation with Flag beads, wild-type or
mutated FH was eluted by a Flag peptide into a total volume
of 100 mL. Afterward, 2–5 mL of eluted protein was added
to 200 mL of enzyme assay buffer (50 mM malate, 10 mM
potassium phosphate at pH 7.3), and the absorbance at OD240
was recorded.
For the SDH complex activity assay, cells were collected at
36 h after transient transfection with wild-type or mutant
SDHA/B plasmids. Afterward, cells were lysed with 600 mL of
enzyme assay buffer (0.1% Triton X-100, 25 mM KHPO4 at pH
7.4) and then incubated with 20 mM succinate, 50 mM decyl-
ubiquinone, 5 mM rotenone, 2 mM Antimycin A, and 10 mM NaN3
for 15 min at room temperature. The reaction was initiated by
adding 50 mM DCIP, and the changes of absorbance at 600 nm
were recorded.
Statistical analysis
Statistical analysis was performed with a two-tailed unpaired
Student’s t-test. All data shown represent the results obtained
from three independent experiments with standard deviations
(mean 6 SD). The value of P < 0.05 was considered statistically
significant.
Acknowledgments
We thank the members of the Fudan MCB laboratory for dis-
cussions and support throughout this study. We appreciate Dr.
Bin Wang for providing cell-permeable octyl-a-KG ester, methyl-
succinate ester, and methyl-fumarate ester. This work was
supported by MOST 973 (nos. 2012CB910300, 2012CB910101,
2011CB910600, and 2009CB918401) and NSFC (grant nos.
30600112, 30871255, 31071192, and 81120108016). This work
was also supported by the 985 Program, Shanghai key project
(grant no. 09JC1402300), the Shanghai Leading Academic Disci-
pline Project (project no. B110), NIH grants (to Y.X. and K.L.G.),
and James McDonnell Foundation and Samuel Waxman Foun-
dation (to Y.X.).
References
Adam J, Hatipoglu E, O’Flaherty L, Ternette N, Sahgal N,
Lockstone H, Baban D, Nye E, Stamp GW, Wolhuter K, et al.
2011. Renal cyst formation in Fh1-deficient mice is indepen-
dent of the Hif/Phd pathway: Roles for fumarate in KEAP1
succination and Nrf2 signaling. Cancer Cell 20: 524–537.
Alam NA, Olpin S, Rowan A, Kelsell D, Leigh IM, Tomlinson IP,
Weaver T. 2005. Missense mutations in fumarate hydratase
in multiple cutaneous and uterine leiomyomatosis and renal
cell cancer. J Mol Diagn 7: 437–443.
Amary MF, Bacsi K, Maggiani F, Damato S, Halai D, Berisha F,
Pollock R, O’Donnell P, Grigoriadis A, Diss T, et al. 2011.
IDH1 and IDH2 mutations are frequent events in central
chondrosarcoma and central and periosteal chondromas but
not in other mesenchymal tumours. J Pathol 224: 306–308.
Astuti D, Latif F, Dallol A, Dahia PL, Douglas F, George E,
Sköldberg F, Husebye ES, Eng C, Maher ER. 2001. Gene
mutations in the succinate dehydrogenase subunit SDHB
cause susceptibility to familial pheochromocytoma and to
familial paraganglioma. Am J Hum Genet 69: 49–54.
Bardella C, Pollard PJ, Tomlinson I. 2011. SDH mutations in
cancer. Biochim Biophys Acta 1807: 1432–1443.
Bayley JP, Launonen V, Tomlinson IP. 2008. The FH mutation
database: An online database of fumarate hydratase muta-
tions involved in the MCUL (HLRCC) tumor syndrome and
congenital fumarase deficiency. BMC Med Genet 9: 20. doi:
10.1186/1471-2350-9-20.
Figure 7. Fumarate and succinate can function as a-KG antag-
onists to broadly inhibit a-KG-dependent dioxygenases, includ-
ing the JMJD family KDMs and the TET family of 5mC
hydroxylases.
Xiao et al.
1336 GENES & DEVELOPMENT
Bayley JP, Kunst HP, Cascon A, Sampietro ML, Gaal J,
Korpershoek E, Hinojar-Gutierrez A, Timmers HJ, Hoefsloot
LH, Hermsen MA, et al. 2010. SDHAF2 mutations in fa-
milial and sporadic paraganglioma and phaeochromocytoma.
Lancet Oncol 11: 366–372.
Baysal BE, Ferrell RE, Willett-Brozick JE, Lawrence EC,
Myssiorek D, Bosch A, van der Mey A, Taschner PE,
Rubinstein WS, Myers EN, et al. 2000. Mutations in SDHD,a
mitochondrial complex II gene, in hereditary paraganglioma.
Science 287: 848–851.
Bennett BD, Kimball EH, Gao M, Osterhout R, Van Dien SJ,
Rabinowitz JD. 2009. Absolute metabolite concentrations
and implied enzyme active site occupancy in Escherichia
coli. Nat Chem Biol 5: 593–599.
Chowdhury R, Yeoh KK, Tian YM, Hillringhaus L, Bagg EA,
Rose NR, Leung IK, Li XS, Woon EC, Yang M, et al. 2011.
The oncometabolite 2-hydroxyglutarate inhibits histone
lysine demethylases. EMBO Rep 12: 463–469.
Damato S, Alorjani M, Bonar F, McCarthy SW, Cannon SR,
O’Donnell P, Tirabosco R, Amary MF, Flanagan AM. 2012.
IDH1 mutations are not found in cartilaginous tumours
other than central and periosteal chondrosarcomas and en-
chondromas. Histopathology 60: 363–365.
Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers
EM, Fantin VR, Jang HG, Jin S, Keenan MC, et al. 2009.
Cancer-associated IDH1 mutations produce 2-hydroxygluta-
rate. Nature 462: 739–744.
Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O’Rourke J,
Mole DR, Mukherji M, Metzen E, Wilson MI, Dhanda A,
et al. 2001. C. elegans EGL-9 and mammalian homologs
define a family of dioxygenases that regulate HIF by prolyl
hydroxylation. Cell 107: 43–54.
Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A,
Li Y, Bhagwat N, Vasanthakumar A, Fernandez HF, et al.
2010. Leukemic IDH1 and IDH2 mutations result in a hyper-
methylation phenotype, disrupt TET2 function, and impair
hematopoietic differentiation. Cancer Cell 18: 553–567.
Hao HX, Khalimonchuk O, Schraders M, Dephoure N, Bayley JP,
Kunst H, Devilee P, Cremers CW, Schiffman JD, Bentz BG,
et al. 2009. SDH5, a gene required for flavination of succinate
dehydrogenase, is mutated in paraganglioma. Science 325:
1139–1142.
Hausinger RP. 2004. FeII/a-ketoglutarate-dependent hydroxylases
and related enzymes. Crit Rev Biochem Mol Biol 39: 21–68.
He YF, Li BZ, Li Z, Liu P, Wang Y, Tang Q, Ding J, Jia Y, Chen Z,
Li L, et al. 2011. Tet-mediated formation of 5-carboxylcyto-
sine and its excision by TDG in mammalian DNA. Science
333: 1303–1307.
Hemerly JP, Bastos AU, Cerutti JM. 2010. Identification of
several novel non-p.R132 IDH1 variants in thyroid carcino-
mas. Eur J Endocrinol 163: 747–755.
Isaacs JS, Jung YJ, Mole DR, Lee S, Torres-Cabala C, Chung YL,
Merino M, Trepel J, Zbar B, Toro J, et al. 2005. HIF over-
expression correlates with biallelic loss of fumarate hydra-
tase in renal cancer: Novel role of fumarate in regulation of
HIF stability. Cancer Cell 8: 143–153.
Ito S, D’Alessio AC, Taranova OV, Hong K, Sowers LC, Zhang Y.
2010. Role of Tet proteins in 5mC to 5hmC conversion, ES-
cell self-renewal and inner cell mass specification. Nature
466: 1129–1133.
Ito S, Shen L, Dai Q, Wu SC, Collins LB, Swenberg JA, He C,
Zhang Y. 2011. Tet proteins can convert 5-methylcytosine to
5-formylcytosine and 5-carboxylcytosine. Science 333: 1300–
1303.
Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, Salic A,
Asara JM, Lane WS, Kaelin WG Jr. 2001. HIF1a targeted for
VHL-mediated destruction by proline hydroxylation: Impli-
cations for O2 sensing. Science 292: 464–468.
Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell
SJ, von Kriegsheim A, Hebestreit HF, Mukherji M, Schofield
CJ, et al. 2001. Targeting of HIF-a to the von Hippel-Lindau
ubiquitylation complex by O2-regulated prolyl hydroxyl-
ation. Science 292: 468–472.
Kaelin WG Jr. 2009. SDH5 mutations and familial paragan-
glioma: Somewhere Warburg is smiling. Cancer Cell 16:
180–182.
King A, Selak MA, Gottlieb E. 2006. Succinate dehydrogenase
and fumarate hydratase: Linking mitochondrial dysfunction
and cancer. Oncogene 25: 4675–4682.
Krivtsov AV, Feng Z, Lemieux ME, Faber J, Vempati S, Sinha AU,
Xia X, Jesneck J, Bracken AP, Silverman LB, et al. 2008. H3K79
methylation profiles define murine and human MLL-AF4
leukemias. Cancer Cell 14: 355–368.
Ling TS, Shi RH, Zhang GX, Zhu H, Yu LZ, Ding XF. 2005.
Common single nucleotide polymorphism of hypoxia-induc-
ible factor-1a and its impact on the clinicopathological
features of esophageal squamous cell carcinoma. Chin J
Dig Dis 6: 155–158.
Loenarz C, Schofield CJ. 2008. Expanding chemical biology of
2-oxoglutarate oxygenases. Nat Chem Biol 4: 152–156.
Lorsbach RB, Moore J, Mathew S, Raimondi SC, Mukatira ST,
Downing JR. 2003. TET1, a member of a novel protein
family, is fused to MLL in acute myeloid leukemia contain-
ing the t(10;11)(q22;q23). Leukemia 17: 637–641.
MacKenzie ED, Selak MA, Tennant DA, Payne LJ, Crosby S,
Frederiksen CM, Watson DG, Gottlieb E. 2007. Cell-perme-
ating a-ketoglutarate derivatives alleviate pseudohypoxia in
succinate dehydrogenase-deficient cells. Mol Cell Biol 27:
3282–3289.
Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD,
Chen K, Koboldt DC, Fulton RS, Delehaunty KD, McGrath
SD, et al. 2009. Recurring mutations found by sequencing
an acute myeloid leukemia genome. N Engl J Med 361:
1058–1066.
Murugan AK, Bojdani E, Xing M. 2010. Identification and
functional characterization of isocitrate dehydrogenase 1
(IDH1) mutations in thyroid cancer. Biochem Biophys Res
Commun 393: 555–559.
Mussini E, Hutton JJ Jr, Udenfriend S. 1967. Collagen proline
hydroxylase in wound healing, granuloma formation, scurvy,
and growth. Science 157: 927–929.
Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K,
Berman BP, Pan F, Pelloski CE, Sulman EP, Bhat KP, et al.
2010. Identification of a CpG island methylator phenotype
that defines a distinct subgroup of glioma. Cancer Cell 17:
510–522.
Oermann EK, Wu J, Guan KL, Xiong Y. 2012. Alterations of
metabolic genes and metabolites in cancer. Semin Cell Dev
Biol. doi: 10.1016/j.semcdb.2012.01.013.
Ooi A, Wong JC, Petillo D, Roossien D, Perrier-Trudova V,
Whitten D, Min BW, Tan MH, Zhang Z, Yang XJ, et al. 2011.
An antioxidant response phenotype shared between heredi-
tary and sporadic type 2 papillary renal cell carcinoma.
Cancer Cell 20: 511–523.
Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P,
Mankoo P, Carter H, Siu IM, Gallia GL, et al. 2008. An
integrated genomic analysis of human glioblastoma multi-
forme. Science 321: 1807–1812.
Pollard PJ, Brière JJ, Alam NA, Barwell J, Barclay E, Wortham NC,
Hunt T, Mitchell M, Olpin S, Moat SJ, et al. 2005. Accumu-
lation of Krebs cycle intermediates and over-expression of
Fumarate and succinate alter epigenetics
GENES & DEVELOPMENT 1337
HIF1a in tumours which result from germline FH and SDH
mutations. Hum Mol Genet 14: 2231–2239.
Rose NR, McDonough MA, King ON, Kawamura A, Schofield
CJ. 2011. Inhibition of 2-oxoglutarate dependent oxygenases.
Chem Soc Rev 40: 4364–4397.
Scatena R, Bottoni P, Giorgia Botta G, Martorana GE, Giardina B.
2007. The role of mitochondria in pharmacotoxicology: A
reevaluation of an old, newly emerging topic. Am J Physiol
Cell Physiol 293: C12–C21. doi: 10.1152/ajpcell.00314.2006.
Selak MA, Armour SM, MacKenzie ED, Boulahbel H, Watson DG,
Mansfield KD, Pan Y, Simon MC, Thompson CB, Gottlieb E.
2005. Succinate links TCA cycle dysfunction to oncogenesis
by inhibiting HIF-a prolyl hydroxylase. Cancer Cell 7: 77–85.
Taguchi K, Motohashi H, Yamamoto M. 2011. Molecular
mechanisms of the Keap1–Nrf2 pathway in stress response
and cancer evolution. Genes Cells 16: 123–140.
Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H,
Brudno Y, Agarwal S, Iyer LM, Liu DR, Aravind L, et al.
2009. Conversion of 5-methylcytosine to 5-hydroxymethyl-
cytosine in mammalian DNA by MLL partner TET1.
Science 324: 930–935.
Tomlinson IP, Alam NA, Rowan AJ, Barclay E, Jaeger EE,
Kelsell D, Leigh I, Gorman P, Lamlum H, Rahman S, et al.
2002. Germline mutations in FH predispose to dominantly
inherited uterine fibroids, skin leiomyomata and papillary
renal cell cancer. Nat Genet 30: 406–410.
Tsukada Y, Fang J, Erdjument-Bromage H, Warren ME, Borchers
CH, Tempst P, Zhang Y. 2006. Histone demethylation by
a family of JmjC domain-containing proteins. Nature 439:
811–816.
Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH, Ito S, Yang C,
Wang P, Xiao MT, et al. 2011. Oncometabolite 2-hydroxy-
glutarate is a competitive inhibitor of a-ketoglutarate-de-
pendent dioxygenases. Cancer Cell 19: 17–30.
Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W,
Kos I, Batinic-Haberle I, Jones S, Riggins GJ, et al. 2009. IDH1
and IDH2 mutations in gliomas. N Engl J Med 360: 765–773.
Yu F, White SB, Zhao Q, Lee FS. 2001. HIF-1a binding to VHL is
regulated by stimulus-sensitive proline hydroxylation. Proc
Natl Acad Sci 98: 9630–9635.
Zhao S, Lin Y, Xu W, Jiang W, Zha Z, Wang P, Yu W, Li Z,
Gong L, Peng Y, et al. 2009. Glioma-derived mutations in
IDH1 dominantly inhibit IDH1 catalytic activity and induce
HIF-1a. Science 324: 261–265.
Xiao et al.
1338 GENES & DEVELOPMENT
